Latest filing published 27 Oct 2023 for Aligos Therapeutics, Inc., €5.7M.
Filing timeline
BuySaleInsider track record
No signal scores available.
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- -44.6%Entry US$16.00 · Close at T+365 US$8.87
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Carole Nuechterlein: trading record in brief
All filings by Carole Nuechterlein on record concern Aligos Therapeutics, Inc. Between 20 October 2020 and 25 October 2023, the trades on record add up to 4 filings.
No open-market sale appears; the market trades are 1 purchase worth €5.7M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Since January 2023: 1 purchase and no sales on the market.
On 27 October 2023 came the latest disclosure, an open-market purchase for €5.7M in Aligos Therapeutics, Inc. Most trades are made public on the day they happen. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Carole Nuechterlein
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 7,933,601 shares@ US$0.7568100.0% of flowCommon StockSEC:0001610717-23-000320:0Canonical exit: 23 Jan 2024 (T+90)
- 2,145,991 sharesCommon StockSEC:0001567619-20-018003:0
- 662,799 sharesCommon StockSEC:0001567619-20-018003:1
- 283,550 sharesCommon StockSEC:0001567619-20-018003:2
4 of 4 declarations
